# Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

> **NCT01532336** · PHASE2 · COMPLETED · sponsor: **NovaBay Pharmaceuticals, Inc.** · enrollment: 500 (actual)

## Conditions studied

- Adenoviral Conjunctivitis

## Interventions

- **DRUG:** NVC-422 Solution, 0.3%
- **DRUG:** NVC-422 Vehicle Solution

## Key facts

- **NCT ID:** NCT01532336
- **Lead sponsor:** NovaBay Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2014-05
- **Final completion:** 2014-08
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2015-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532336, "Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01532336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*